Table 1.

Efficacy results for ibrutinib clinical trials

MCLCLL
Efficacy endpointN = 111N = 48
ORR (95% CI)65.8% (56.2%–74.5%)58.3% (43.2%–72.4%)
Complete response17.1%0
Partial response48.6%58.3%
Duration of responseN = 73N = 28
 Median17.5 monthsNot reached
 Range0.4 to 19.6+ months5.6 to 24.2+ months